Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Director Chandra P. Leo Acquires 10,000 Shares

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Director Chandra P. Leo acquired 10,000 shares of the firm’s stock in a transaction on Monday, March 24th. The stock was purchased at an average price of $5.84 per share, for a total transaction of $58,400.00. Following the completion of the transaction, the director now directly owns 10,000 shares in the company, valued at approximately $58,400. The trade was a ? increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Monte Rosa Therapeutics Trading Down 2.7 %

NASDAQ GLUE opened at $5.67 on Wednesday. Monte Rosa Therapeutics, Inc. has a 12 month low of $3.21 and a 12 month high of $12.40. The stock has a 50-day simple moving average of $6.19 and a 200 day simple moving average of $6.78. The company has a market capitalization of $348.35 million, a PE ratio of -3.10 and a beta of 1.50.

Monte Rosa Therapeutics (NASDAQ:GLUE) last announced its quarterly earnings results on Thursday, March 20th. The company reported $0.23 EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.60. The company had revenue of $14.00 million during the quarter, compared to the consensus estimate of $43.73 million. As a group, sell-side analysts predict that Monte Rosa Therapeutics, Inc. will post -1.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Monte Rosa Therapeutics

Several hedge funds have recently bought and sold shares of the company. Tower Research Capital LLC TRC grew its holdings in shares of Monte Rosa Therapeutics by 192.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,443 shares of the company’s stock valued at $38,000 after buying an additional 3,584 shares during the period. GAMMA Investing LLC grew its stake in Monte Rosa Therapeutics by 10,665.5% in the fourth quarter. GAMMA Investing LLC now owns 5,921 shares of the company’s stock valued at $41,000 after acquiring an additional 5,866 shares during the period. BNP Paribas Financial Markets acquired a new position in Monte Rosa Therapeutics in the fourth quarter valued at about $43,000. Virtus ETF Advisers LLC bought a new stake in shares of Monte Rosa Therapeutics in the fourth quarter worth about $63,000. Finally, Focus Partners Wealth acquired a new stake in shares of Monte Rosa Therapeutics during the fourth quarter worth about $77,000. 79.96% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently issued reports on GLUE. Wedbush reiterated an “outperform” rating and issued a $17.00 price target (up previously from $15.00) on shares of Monte Rosa Therapeutics in a report on Thursday, March 20th. Lifesci Capital began coverage on shares of Monte Rosa Therapeutics in a research report on Wednesday, March 12th. They set an “outperform” rating and a $19.00 price target for the company. Finally, Wells Fargo & Company cut their price objective on shares of Monte Rosa Therapeutics from $11.00 to $10.00 and set an “equal weight” rating on the stock in a report on Friday, March 21st.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.